In risk management planning, the European Directives does dictate different handling when it comes to some residual drugs versus others. The group A substances are considered as some of the most harmful. Hence the EU directives dictate a zero tolerance policy when it comes to these types of drugs. Risk management is done by having a clear scientific understanding of what type of residual drug might have what impact. The Group A residual drug will have a worse impact and hence are considered to be more of a high risk. However, the risk frequency occurrence is not considered when planning for risk management.
The zero tolerance approach furthermore will be considered only based on the type of screening that is used, the confirmation methods and more (EMA, 2016). Although the EU directive is used across all the countries that have accepted the codes, some of these issues of standardization could result in vulnerabilities. Sample noncompliance is usually declared based on some key criteria. In the case of group B substances, the screening methods are not as stringent as in the case of Group A given that the Group B substances have less or no adverse impact compared to Group A. Usually a sample that has been selected from this group will be considered to be non-complaint based on residual checks that is done. In the risk impact matrix that has been presented below (without considering probability) the Group A residual drugs and their impact would be classified as medium to high impact. Based on the probability of occurrence they would be elevated to yellow and red status in the matrix.